《新股》德勤上調香港今年新股集資額預測至2,000億元
德勤中國資本市場服務部發表2025年上半年香港新股市場回顧,數據顯示,上半年香港共錄40宗IPO,合共集資1,021億元,宗數按年增加33%,集額總額更大升超過6.7倍,當中有近75%集資額都來自於4隻超大型A+H新股及1隻H股上市。上半年香港重回全球新股集資排行榜首位,拋離分別集資713億及590億元的納斯達克交易所與紐約交易所。
目前香港有超過170宗正在處理的上市申請個案,當中有超過5間公司或將各自集資至少10億美元。德勤中國資本市場服務部預計,2025年全年香港新股上市宗數將達到80宗,預測合計集資2,000億元,較該行去年底預測的1,300億至1,500億元上調最多53.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.